A detailed history of Ruggaard & Associates LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Ruggaard & Associates LLC holds 354 shares of REGN stock, worth $400,551. This represents 0.17% of its overall portfolio holdings.

Number of Shares
354
Previous 352 0.57%
Holding current value
$400,551
Previous $339 Million 9.82%
% of portfolio
0.17%
Previous 0.16%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$883.2 - $1071.19 $1,766 - $2,142
2 Added 0.57%
354 $372 Million
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $9,026 - $9,933
10 Added 2.92%
352 $339 Million
Q4 2023

Feb 15, 2024

SELL
$775.18 - $881.7 $47,285 - $53,783
-61 Reduced 15.14%
342 $300 Million
Q3 2023

Nov 09, 2023

SELL
$692.45 - $844.37 $1,384 - $1,688
-2 Reduced 0.49%
403 $332 Million
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $275,598 - $334,922
405 New
405 $333 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $121B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Ruggaard & Associates LLC Portfolio

Follow Ruggaard & Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ruggaard & Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ruggaard & Associates LLC with notifications on news.